Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05122650 · ClinicalTrials.gov registry record · Phase 2

A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)

A Phase 2 study of Essential Tremor, sponsored by Jazz Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
420
Enrollment target
20
Study locations

NCT05122650 is a Phase 2 study of Essential Tremor that has completed, run by Jazz Pharmaceuticals. The registered enrollment target is 420 participants, roughly in line with the 392-participant average among 41 other Essential Tremor trials with a reported enrollment target. The trial reports 20 study locations across 5 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05122650, a Phase 2 study of Essential Tremor, has completed, sponsored by Jazz Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
420 participants
Enrollment target
20
Study locations

Study Summary

This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.

Conditions Studied

Essential Tremor

Interventions

  • OTHER Placebo
  • DRUG JZP385

Study Locations (20)

Florida

  • Neurology of Central Florida Research Center - Altamonte Springs
  • JEM Research Institute - Atlantis
  • Parkinson's Disease And Movement Disorder Center Of Boca Raton - Boca Raton
  • Innovative Research Of West Florida, Inc. - Clearwater
  • Infinity Clinical Research, Llc - Hollywood
  • Clinical Neuroscience Solutions, Inc. - Jacksonville
  • Homestead Associates in Research, Inc. - Miami
  • USF Carol and Frank Morsani Center for Advanced Healthcare - Tampa

Arizona

  • St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center - Phoenix
  • Arizona Neuroscience Research, LLC - Phoenix
  • Imaging Endpoints II, LLC - Scottsdale
  • Movement Disorders Center of Arizona - Scottsdale
  • Banner Sun Health Research Institute - Sun City

California

  • The Parkinson's and Movement Disorder Institute - Fountain Valley
  • Keck School of Medicine USC - Healthcare Consultation Center 2 (HCCII) - Los Angeles
  • SC3 Research - Beverly - Los Angeles
  • SC3 Research Pasadena - Pasadena

Arkansas

  • Pillar Clinical Research, LLC - Bentonville
  • Woodland Research Northwest, LLC - Rogers

Alabama

  • The University Of Alabama At Birmingham (Uab) - Birmingham

Trial Details

FieldValue
Enrollment Target 420 participants
Start Date 2021-12-06
Est. Completion 2024-05-30
Phase Phase 2

Sponsor

Jazz Pharmaceuticals

128 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05122650

The ClinicalTrials.gov registry entry for NCT05122650 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 420 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 392-participant average among 41 other Essential Tremor trials with a reported enrollment target. The listed sponsor is Jazz Pharmaceuticals, which has 128 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Essential Tremor appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05122650 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, Arizona, California.

Frequently Asked Questions

What is clinical trial NCT05122650 about?

NCT05122650 is a clinical study titled "A Study To Assess the Safety and Efficacy of JZP385 in the Treatment of Adults With Moderate to Severe Essential Tremor (ET)". This is a 12-week, double-blind, placebo-controlled, randomized, parallel-group, multicenter study of the safety and efficacy of JZP385 in the treatment of adult participants with moderate to severe ET.

What is the current status of trial NCT05122650?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 420 participants. The study started on 2021-12-06. Estimated completion is 2024-05-30.

What conditions does trial NCT05122650 study?

This clinical trial studies the following conditions: Essential Tremor.

What interventions are being tested in trial NCT05122650?

The interventions under investigation include: Placebo (OTHER), JZP385 (DRUG).

Who is sponsoring clinical trial NCT05122650?

This trial is sponsored by Jazz Pharmaceuticals, which has 128 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05122650 being conducted?

This trial has 20 study locations across Alabama, Arizona, Arkansas, California, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Essential Tremor

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Essential Tremor

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.